UBE2D3 Activates SHP-2 Ubiquitination to Promote Glycolysis and Proliferation of Glioma via Regulating STAT3 Signaling Pathway

Zhenjiang Pan†, Jing Bao†, Liujun Zhang and Shepeng Wei*

Department of Neurosurgery, Shidong Hospital of Yangpu District in Shanghai, Shanghai, China

Glioma is a primary brain cancer with high malignancy and morbidity. Current management for glioma cannot reach optimal remission. Therefore, it is necessary to find novel targets for glioma treatment. Ubiquitin-conjugating enzyme E2 D3 (UBE2D3) is involved in the pathogenesis of various kinds of cancer. However, its role in glioma remains unclear. Our study aims to explore the function and underlying mechanism of UBE2D3 in the development of glioma. By analysis with The Cancer Genome Atlas-Glioblastoma multiforme (TCGA-GBM) dataset, we found that UBE2D3 was highly expressed in glioma and it is positive correlation with glycolysis, apoptosis, and STAT3 pathway. Then, we explore the effects of UBE2D3 knockdown in the biological functions of glioma cell lines. Cell proliferation and apoptosis were estimated by cell counting kit-8 assay and flow cytometry. Extracellular acidification rate and oxygen consumption rate were estimated to determine the level of cell glycolysis. Xenograft experiments were performed to identify in vivo function of UBE2D3. The results showed that the inhibition of UBE2D3 could suppress the proliferation, glycolysis, and STAT3 phosphorylation of GBM both in vitro and in vivo. UBE2D3 could interact with SHP-2 and promoted its ubiquitination, which elevated the activation of STAT3 pathway. Overexpressed SHP-2 could reverse the effect of UBE2D3 and they shared contrary expression patterns in glioma and normal brain tissues. In summary, our study revealed that UBE2D3 could promote the ubiquitination of SHP-2, which activated STAT3 pathway and promoted glioma proliferation as well as glycolysis. UBE2D3 could be a potential target for glioma treatment.

Keywords: glioma, UBE2D3, SHP-2, ubiquitination, STAT3, glycolysis

INTRODUCTION

Gliomas are the most common type of brain cancer with morbidity of 7-8 cases per 100,000 people (1). Clinical classification of gliomas includes four grades according to the World Health Organization (WHO) classification, in which a higher grade indicates a worse prognosis (2). Glioblastoma multiforme (GBM) is the most malignant type of glioma that is classified as grade IV glioma. The medium overall survival time of GBM patients is approximately 13 months (3). Conventional management include maximal surgical resection, chemotherapy and radiotherapy. However, tumor recurrence remains a
challenge and only two drugs have been approved by the Food and Drug Administration in the past decade (4). Therefore, there is a clear urgent to find novel targets for the treatment of glioma.

Ubiquitin-conjugating enzyme E2 D3 (UBE2D3) is a member of ubiquitin-conjugating enzyme (E2) family, which is involved in the protein ubiquitination along with ubiquitin-activating enzyme (E1) and ubiquitin-protein ligase (E3) (5). Multiple studies have reported the role of ubiquitination in the progression of cancer (6). The ubiquitination of tumor suppressors such as p53 could facilitate the proliferation of cancer (7). UBE2D3 has been implicated to be involved in the development and progression of various types of cancer including esophageal cancer, breast cancer and acute promyelocytic leukemia (8–10). However, its role in glioma remains unclear.

Signal transducer and activator of transcription 3 (STAT3) has been implicated to play an oncogenic role in various cancers including glioma (11). The phosphorylation of STAT3 can promote the proliferation of tumor cells, in which phosphatases such as Src homology-2-containing protein tyrosine phosphatase 1 (SHP-1), SHP-2, SOCS1, SOCS3, and PTP1B can induce the dephosphorylation (12). Previous studies indicated that STAT3 could promote tumor progression and was associated with the efficacy of targeted therapy (13, 14). In the meantime, the progression of cancer cells requires large amounts of energy, in which a high rate of glycolysis can facilitate the proliferation and mediate chemoresistance. Therefore, strategies targeting glycolysis remains attractive for cancer treatment (15).

A previous study indicated that the inhibition of STAT3 could suppress the proliferation and the glycolysis of glioma cells (16). However, the underlying mechanism requires additional exploration. Our study was conducted to explore the role of UBE2D3 and its molecular mechanism in the pathogenesis of glioma, aiming to provide a novel target for glioma treatment.

MATERIALS AND METHODS

Bioinformatics Analysis
RNA expression data of 168 GBM and 5 normal brain samples were downloaded from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/). The potential pathway of UBE2D3 was predicted by Gene Set Enrichment Analysis (GSEA), which was performed between UBE2D3 high and low groups with the cutoff p-value of 0.01 as previously described (17, 18). Gene sets with fewer than 10 genes were excluded.

Glioma Sample Collection
Glioma tissues were obtained from patients who received surgery at Shidong hospital of Yangpu district in Shanghai with informed written consent collected. All specimens were frozen in liquid nitrogen for further experiments. This study was approved by the Ethics Committee of Shidong Hospital of Yangpu District in Shanghai.

Immunohistochemistry
Paraffin-embedded glioma specimens were cut at 4 μm. The xylene and graded ethanol were used for deparaffinization and rehydration. Citrate buffer (pH=6.0) was used for antigen retrieval. Then the slides were blocked by 0.3% hydrogen peroxide and 5% bovine serum albumin. After the incubation with the primary antibody and secondary antibody, DAB staining kit and hematoxylin were used for staining. The intensity was calculated as follows: intensity × percentage of positive cells. The intensity was determined as 0, negative; 1, weak; 2, moderate; 3, strong. The estimation of staining was conducted by two investigators independently. Primary antibodies included UBE2D3 (Proteintech, 11677-1-AP) and SHP-2 (Abcam, Ab32159).

Cell Culture and Cell Transduction
T98G, U87 and U251 cells were purchased from Cell Bank of Shanghai Institute of Cell Biology. Cells were incubated in 37°C with 5% CO₂, DMEM medium (Gibco, USA) with 10% fetal bovine serum (Gibco, USA) was used for cell culture. To reduce the expression of UBE2D3, three short hairpin RNAs (shRNAs) were designed and cloned into plKO.1 (Addgene, Cambridge, MA, USA). The sequence of three shRNAs were as follows: shUBE2D3-1, 5'- CCCTTCAGCAACATGGTTCCT -3'; shUBE2D3-2, 5'- CTTAAAGTTGGATTTACA -3'; shUBE2D3-3, 5'- GCAGCATTTGTCTCGATAT -3'. The full-length human UBE2D3 and SHP-2 was cloned into plLVX-puro vector (Clontech, USA) to overexpress UBE2D3 (oeUBE2D3) and SHP-2 (oeSHP-2), respectively. The corresponding lentivirus was produced in 293T cells with packaging plasmids.

Quantitative Real-Time PCR (qRT-PCR)
Total RNA was extracted using TRIzol reagent (Life Technology) and cDNA was synthesized (Takara, Japan). Reactions were performed on ABI-7300 system (Applied Biosystem, USA) according to the manufacturer’s instructions. Gene expression was normalized to β-actin. The primer sequences were as follows: SHP-2, F, TGCGGTGATGCGGTGTAG; R, AGGT CCGAAAATGTTATGTC. β-actin, F, TGGCATATGGCGA CAGG; R, GCATTGCGGGATAG.

Western Blotting
Cells were lysed in RIPA buffer (Beyotime, China). The protein was separated in 10% SDS-PAGE gel and transferred to nitrocellulose membranes. The 5% non-fat milk was applied to the membrane to block non-specific antigens. After incubation with primary and secondary antibodies (Beyotime Biotech.), the protein content was detected using an ECL kit (Pierce, USA). Primary antibodies used in this study were as follows: UBE2D3 (Abcam, Ab176568); STAT3 (Abcam, Ab68153); p-STAT3 (Abcam, Ab76315); HK2 (Abcam, Ab209847); PFKL (Abcam, Ab181064); PTP1B (Abcam, Ab244207); SHP-1 (Abcam, Ab32559); SHP-2 (Abcam, Ab32159); SOCS1 (Abcam, Ab62584); SOCS3 (Abcam, Ab16030); Ubiquitin (Abcam, Ab7780); β-actin (Abcam, Ab8227).

Cell Proliferation Assay
Cell proliferation of glioma cells was determined using Cell Counting Kit-8 (Dojindo, Japan). Cells were inoculated in 96-well plates after transduction. 10 μl CCK-8 reagents were added to each well and incubated at 37°C for 1 hour. The optical density
(OD) value at 450 nm wavelength was detected by Multiskan MS plate reader (Labsystems, Finland).

**Cell Apoptosis Analysis**

Cell apoptosis of glioma cells was estimated by Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (BD, 556547, USA). Cells were collected, washed twice with PBS, and incubated with Annexin V and propidium iodide (PI). The analysis was conducted by a flow cytometer (BD Biosciences, USA).

**Measurement of 2-NBDG Uptake and Lactate Production**

The glioma cells were treated as indicated for 24 h. Glucose uptake was examined with using 2-NBDG (2-[(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxyglucose; Cayman, Ann Arbor, MI, USA) as previously described (19). After normalization of the protein content, the values of the control group were set as 1.0, and the others were relative it.

The culture medium was collected and lactate production was assessed with a lactic acid detection kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer’s protocol.

**Estimation of Cell Glycolysis**

Cell glycolysis was evaluated via estimating extracellular acidification rate (ECAR) and oxygen consumption rate (OCR). The Glycolysis Stress Test Kit (Seahorse Bioscience) was used for ECAR assessment, whereas the Extracellular Oxygen Consumption Assay kit was used for OCR assessment according to the manufacturer’s instruction. Level of ECAR and OCR was normalized to the protein content. Glycolytic capacity was calculated as the mean value of three ECAR measurements following the addition of oligomycin, while glycolytic reserve was calculated based on the difference between the basal ECAR and glycolytic capacity according to the manufacturer’s instruction.

**Co-Immunoprecipitation (Co-IP) Assays**

Cell lysates were incubated with anti-UBE2D3 (Abcam, Ab249927), anti-SHP-2 (Abcam, Ab187040) or control IgG (Santa Cruz Biotech., USA) antibodies for 1 hour at 4°C. The immunocomplex was collected using protein A/G-agarose (Santa Cruz Biotech., USA). Precipitates were washed three times in lysis buffer and collected for western blot analysis.

**Xenograft Experiments**

To explore the effect of UBE2D3 in vivo, BALB/c nude mice (4-5 weeks old) were divided into two groups (n=6). A total of 5 × 10^6 U87 cells transduced with shUBE2D3-1 and shNC lentivirus were injected into mice subcutaneously. Tumor volume was estimated every three days. On Day 33, the tumors were collected for further experiments such as real-time PCR, western blotting and TUNEL assay. Our study was approved by the Committee on Animal Care and Use of Shidong Hospital of Yangpu District in Shanghai.

**Statistical Analysis**

Statistical analysis was conducted using Graphpad Prism software version 7.0 (CA, USA). Quantitative data were presented as mean ± standard deviation. For difference comparison, Student’s t-test and one-way ANOVA were conducted for two groups or more than two groups, respectively. P values less than 0.05 were considered as statistically significant.

**RESULTS**

**UBE2D3 Was Highly Expressed in GBM and Enriched in Glycolysis, Apoptosis, and STAT3 Signaling Pathway**

To characterize the role of UBE2D3 in GBM, we extracted data from TCGA-GBM dataset. Results showed that the expression of UBE2D3 was significantly elevated in GBM compared with normal brain tissue (p < 0.05) (Figure 1A). Then we explored the potential molecular mechanisms of UBE2D3 in GBM. A total of 1,473 genes were correlated with UBE2D3 expression in TCGA-GBM dataset (Table S1). GESA analysis showed that cell glycolysis, cell apoptosis, and STAT3 signaling pathways were highly enriched in UBE2D3 highly expressed samples (Figures 1B–D). Therefore, UBE2D3 might play an oncogenic role in GBM via regulating cell glycolysis, cell apoptosis, and STAT3 signaling pathways.

**Knockdown of UBE2D3 Suppressed the Proliferation, Glycolysis, and STAT3 Phosphorylation, but Induced Apoptosis in Glioma Cells**

Then we explored the role of UBE2D3 in GBM via in vitro experiments. The expression of UBE2D3 was higher in glioma cell lines especially in T98G and U87 compared with normal brain tissues (Figure S1A). Specific shRNAs targeting UBE2D3 were transduced and successfully inhibited the expression of UBE2D3 compared with the control group in T98G and U87 cells (Figures 2A and S1C, D). The inhibition of UBE2D3 significantly reduced the proliferation and elevated the apoptosis of GBM cells (p < 0.05) (Figures 2B, C). Moreover, lactate production and glucose uptake was remarkably reduced after the knockdown of UBE2D3 in GBM cells (Figures 2D, E). ECAR (Figure 2F), glycolytic capacity, glycolytic reserve (Figure 2G) and OCR (Figure 2H) were notably reduced after the knockdown of UBE2D3 in GBM cells. In the meantime, two crucial enzymes for glycolysis, hexokinase-2 (HK-2) and 6-phosphofructokinase (PFKL), were markedly suppressed with the inhibition of UBE2D3 (Figure 2I). In contrast, the transduction of UBE2D3 overexpressed virus significantly elevated the expression of UBE2D3 and the proliferation of U251 cells, a cell line with lower expression of UBE2D3 (p < 0.05) (Figures S1E, S2A, B), but suppressed cell apoptosis (Figure S2C). Besides, the elevated expression of UBE2D3 notably promoted the glycolysis of U251 cells (Figures S2D–F). Moreover, the protein level of HK-2, PFKL, and p-STAT3 was increased by the overexpression of UBE2D3 (Figure S2G). The level of p-STAT3 was higher in
glioma cell lines compared with normal brain tissues (Figure S1B). These results indicated that the inhibition of UBE2D3 could suppress the proliferation, glycolysis and STAT3 phosphorylation, and induce the apoptosis of GBM cells.

**Inhibition of UBE2D3 Suppressed Cell Proliferation and STAT3 Phosphorylation as Well as Inducing Cell Apoptosis In Vivo**

Further, we developed mice xenograft models to validate the pathogenic role of UBE2D3 in GBM in vivo. Results showed that the inhibition of UBE2D3 significantly reduced the tumor volume and tumor weight ($p < 0.05$) (Figures 3A, B). Moreover, the TUNEL signal was higher in the shUBE2D3 group compared to the control group (Figure 3C). The expression of UBE2D3, p-STAT3, HK-2, and PFKL was reduced in the tumor of the shUBE2D3 group whereas that of STAT3 exhibited no significant alternation (Figure 3D). These findings demonstrated that UBE2D3 played an oncogenic role in GBM and its inhibition could suppress tumor growth.

**UBE2D3 Interacted With SHP-2 and Promoted Its Ubiquitination**

To further explore the molecular mechanism of UBE2D3 in the pathogenesis of GBM, we detected the expression of several phosphorylases of STAT3 including SHP-1, SHP-2, SOCS1, SOCS3 and PTP1B. Results showed that the inhibition of UBE2D3 notably promoted the expression of SHP-2 whereas that of other phosphorylases did not exhibit significant changes (Figure S3). Although the protein level of SHP-2 was elevated, its mRNA level had no significant difference ($p > 0.05$) (Figure 4A). Similarly, the overexpression of UBE2D3 markedly reduced the protein level of SHP-2 but showed no effect on its mRNA level ($p > 0.05$) (Figure 4B). Therefore, UBE2D3 might interact with SHP-2 and affect its post-transcriptional modification. Co-IP assay revealed...
that UBE2D3 interacted with SHP-2 (Figure 4C). Although the overexpressed UBE2D3 could decrease the expression of SHP-2, the application of MG132 could reverse this effect (Figure 4D). The inhibition of UBE2D3 notably decreased the ubiquitination of SHP-2 and subsequently promoted its expression (Figure 4E). These results suggested that UBE2D3 could interact with SHP-2 and decrease its protein level via promoting ubiquitination.

The SHP-2 inhibitor PHPS1 Reversed the Effects of UBE2D3 Knockdown

Then we verified the interaction between UBE2D3 and SHP-2 in U87 and T98G cells. Western blot revealed that the expression of p-STAT3 was suppressed by the SHP-2 inhibitor PHPS1, which was reversed from the effect of UBE2D3 knockdown (Figure 5A). Moreover, PHPS1 significantly elevated the proliferation of U87...
and T98G cells with UBE2D3 knockdown (p < 0.05) (Figure 5B). Similarly, the glycolysis of U87 and T98G cells were inhibited by UBE2D3 knockdown but promoted by PHPS1 (Figures 5C–E). These findings validated UBE2D3 and SHP-2 played a competing role in GBM cells.

Overexpressed SHP-2 Reversed the Effects of UBE2D3

Then SHP-2 overexpressed virus was transduced into U251 cells, which markedly promoted the expression of SHP-2 (Figure S1F). Although the overexpression of UBE2D3 reduced the expression of SHP-2, the transduction of oeSHP-2 could promote its expression in rescue (Figure 6A). Moreover, the elevation of SHP-2 significantly inhibited the proliferation and increased the apoptosis of U251 cells which were UBE2D3 overexpressed (p < 0.05) (Figures 6B–C). Similarly, glycolysis of U251 cells were promoted by overexpressed UBE2D3 but inhibited by overexpressed SHP-2 (Figures 6D–F). Additionally, western blot revealed that the expression of HK-2, PFKL, and p-STAT3 was suppressed by SHP-2, which was reversed from the effect of UBE2D3 (Figure 6G). These findings also validated the competing role of UBE2D3 and SHP-2 in GBM cells.

UBE2D3 and SHP-2 Exhibited Reversed Expression Pattern in Glioma Specimens

Further, we detected the expression pattern of UBE2D3 and SHP-2 in glioma specimens to validate their interactions. In normal brain tissue, the expression of UBE2D3 was relatively low whereas that of SHP-2 was highly expressed (Figure 7A). Besides, in patients with high expression of UBE2D3 (Case 1), the expression of SHP-2 was moderate. In contrast, in those with low expression of UBE2D3 (Case 2), the expression of SHP-2 was relatively high. In 86 glioma specimens, the expression of UBE2D3 and SHP-2 exhibited reversed expression pattern (p < 0.05) (Figure 7B). These results further validated the competing role between UBE2D3 and SHP-2 in glioma.

DISCUSSION

Current management of glioma cannot reach optimal remission. Therefore, it is necessary to find novel targets for the development of therapeutics against glioma. Our study revealed that UBE2D3 was highly expressed in GBM and its expression pattern was

**FIGURE 3** | Inhibition of UBE2D3 suppressed cell proliferation and STAT3 phosphorylation as well as inducing cell apoptosis in vivo. (A, B) The volume (A) and weight (B) of subcutaneous tumors derived from mice model. U87 cells transduced with shUBE2D3-1 and NC lentivirus were subcutaneously injected in mice (n=6 per group). (C) TUNEL assay of tumors derived from mice model. Magnification, 400×. (D) The expression of UBE2D3, STAT3, p-STAT3, HK-2 and PFKL in tumors derived from mice model. *p < 0.01.
reversed from SHP-2. The inhibition of UBE2D3 could suppress the proliferation, glycolysis, and STAT3 phosphorylation of GBM by promoting the ubiquitination of SHP-2. These findings could provide novel insights into the pathogenesis of GBM and UBE2D3 was a potential target for glioma treatment.

Ubiquitination is a crucial post-transcriptional modification mediated by the ubiquitin-proteasome system that is critical for cancer development. As a key factor for ubiquitination, E2 enzyme family members are involved in the DNA repair, tumor progression, and drug resistance (20). A previous study indicated that UBE2D3 was a protective factor for esophageal cancer patients and its knockdown could significantly increase radioresistance and maintain telomerase activity (8). Moreover, UBE2D3 could modulate the radioresitivity of breast cancer through regulating the activity of human telomerase reverse transcriptase (9). In contrast, UBE2D3 seemed to play an oncogenic role in glioma since our study revealed that UBE2D3 was highly expressed in GBM compared to normal brain tissues. Besides, UBE2D3 could increase the proliferation rate of GBM cells. The inhibition of UBE2D3 significantly reduced the tumor growth in mice xenograft models, indicating that UBE2D3 could be a potential target for glioma treatment.

SHP-2 has been implicated to be a key protein involved in oncogenic signaling pathways such as RAS-ERK, PI3K-AKT, and JAK-STAT3 pathway (21). In myeloma, SHP-2 can reduce the phosphorylation of STAT3 and thus suppress its activation (22). The deletion of SHP-2 can promote the development of hepatocellular carcinoma via the activation of IL-6-STAT3 pathway (23). Moreover, SHP-2 expression is significantly decreased in colon cancer and its expression is negatively correlated with tumor differentiation, clinical stage, and lymph node metastasis (21).
These findings indicated the protective role of SHP-2 in the development of malignancies. Our study revealed that the overexpression of SHP-2 significantly reduced the proliferation, glycolysis and STAT3 phosphorylation in GBM cells. Our study firstly revealed that SHP-2 acts as a tumor suppressor in glioma. The activity of SHP-2 was suppressed by UBE2D3 which promoted its ubiquitination. The SHP-2 inhibitor PHPS1 reversed the tumor-suppressive effects of UBE2D3 knockdown, while SHP-2 overexpression blocked the oncogenic effects of UBE2D3 overexpression. Besides, SHP-2 exhibited reversed expression pattern compared with UBE2D3 in glioma tissues. These data suggested that UBE2D3 exerted functions in glioma via SHP-2.

Activated glycolysis is reported to be associated with the progression of glioma (24). The blockade of glucose transporters and glycolytic enzymes exhibited promising anticancer effects in preclinical models (15). Our data firstly showed that the glycolysis process and the expression of glycolytic enzymes, HK-2 and PFKL, in glioma cells were suppressed upon the knockdown of UBE2D3. The activation of STAT3 pathway and the high level of glycolysis could facilitate the progression of cancer cells. A previous study indicated that STAT3 could promote aerobic glycolysis through targeting hexokinase 2 in hepatocellular carcinoma (25). Similarly, the reduction of STAT3 was accompanied with decreased level of aerobic glycolysis in head and neck squamous cell carcinoma (26). The inhibition of STAT3 could suppress the growth of glioma stem cells effectively combined with radiotherapy (27). Besides, it has been reported that STAT3 signaling pathway regulated the expression of HK-2 and PFKL (28, 29). In the current study, we found that UBE2D3 knockdown inhibited STAT3 phosphorylation in vitro and in vivo. Our preliminary data showed that a STAT3
FIGURE 6 | Overexpressed SHP-2 reversed the effects of UBE2D3. (A) The expression of SHP-2 after transduced with SHP-2 overexpressed lentivirus in U251 cells with overexpressed UBE2D3 or not. (B, C) Cell proliferation (B) and apoptosis (C) of U251 cells with overexpressed SHP-2 and UBE2D3 or not. (D, E) Extracellular acidification rate (D), glycolytic capacity, glycolytic reserve (E) and oxygen consumption rate (F) of U251 cells with overexpressed SHP-2 and UBE2D3 or not. (G) Expression of HK-2, PFKL, STAT3, and p-STAT3 in U251 cells with overexpressed SHP-2 and UBE2D3 or not. *p < 0.05; **p < 0.01; ***p < 0.001.

FIGURE 7 | UBE2D3 and SHP-2 exhibited reversed expression pattern in glioma specimens. (A) Immunohistochemistry staining of UBE2D3 and SHP-2 in representative glioma specimens. Case 1 represented UBE2D3 high but SHP-2 low specimens; Case 2 represented UBE2D3 low but SHP-2 high specimens. (B) Statistical analysis of the expression of UBE2D3 and SHP-2 in each glioma specimen (Fisher’s exact test).
inhibitor could inhibited UBE2D3 overexpression-induced STAT3 phosphorylation in glioma cells (data not shown). However, whether UBE2D3 regulated glycolysis process and the glycolytic enzymes via STAT3 is needed to be elucidated in the future.

Through the conduct of in vitro and in vivo experiments, we demonstrated that the interaction between UBE2D3 and SHP-2 was associated with STAT3 pathway and cell glycolysis. However, we did not reveal the underlying mechanism of UBE2D3 and SHP-2 in regulating the glycolysis of glioma cells. Besides, the association between UBE2D3 and the efficacy of chemotherapy or radiotherapy required further investigation. Nevertheless, our study revealed a novel molecular mechanism underlying glioma development and could provide novel targets for glioma treatment.

To sum up, our study revealed that UBE2D3 could interact with SHP-2 and promote its ubiquitination, which activated STAT3 could provide novel targets for glioma treatment. UBE2D3 could be a potential target for glioma treatment.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

REFERENCES

1. Ostrom QT, CiofﬁG, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol (2019) 21 (Supplement 3):v1–100. doi: 10.1093/neuonc/noz150
2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classiﬁcation of Tumors of the Central Nervous System: A Summary. Acta Neuropathol (2016) 131(6):803–20. doi: 10.1007/s00401-016-1545-1
3. Bleeker FE, Molenaar RJ, Leenstra S. Recent Advances in the Molecular Understanding of Glioblastoma. J Neurooncol (2012) 108(1):11–27. doi: 10.1007/s11060-011-0793-0
4. Xu S, Tang L, Li X, Fan F, Liu Z. Immunotherapy for Glioma: Current Management and Future Application. Cancer Lett (2020) 476:1–12. doi: 10.1016/j.canlet.2020.02.002
5. Popovic D, Vucic D, Dikic I. Ubiquitination in Disease Pathogenesis and Treatment. Nat Med (2014) 20(11):1242–53. doi: 10.1038/nm.3739
6. Mansour MA. Ubiquitination: Friend and Foe in Cancer. Int J Biochem Cell Biol (2018) 101:80–93. doi: 10.1016/j.biocel.2018.06.001
7. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in Oncogenesis and Cancer Therapy. Nat Rev Cancer (2013) 13(2):83–96. doi: 10.1038/nrc3430
8. Yang H, Wu L, Ke S, Wang W, Yang L, Gao X, et al. Downregulation of Ubiquitin-Conjugating Enzyme UBE2D3 Promotes Telomere Maintenance and Radioresistance of Eca-109 Human Esophageal Carcinoma Cells. J Cancer (2016) 7(9):1152–62. doi: 10.7150/jca.14745
9. Wang W, Yang L, Hu L, Li F, Ren L, Yu H, et al. Inhibition of UBE2D3 Expression Attenuates Radioresistance of MCF-7 Human Breast Cancer Cells by Increasing hTERT Expression and Activity. PLoS One (2013) 8(5):e64660. doi: 10.1371/journal.pone.0066660
10. Hattori H, Zhang X, Jia Y, Subramanian KK, Jo H, Loison F, et al. RNAi Screen Identifies UBE2D3 as a Mediator of All-Trans Retinoic Acid-Induced Cell Growth Arrest in Human Acute Promyelocytic NB4 Cells. Blood (2007) 110(2):640–50. doi: 10.1182/blood-2006-11-059048
11. Ouedraogo ZG, Biau J, Kemeny JL, Morel L, Verrelle P, Chautard E. Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. Mol Neurobiol (2017) 54(8):5780–97. doi: 10.1007/s12035-016-1013-0

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of Shidong Hospital of Yangpu District in Shanghai. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by the Committee on Animal Care and Use of Shidong Hospital of Yangpu District in Shanghai.

AUTHOR CONTRIBUTIONS

SW and ZP designed the experiments. ZP, JB, and LZ performed the experiments. ZP and JB performed the statistical analysis, and wrote the manuscript. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/onc.2021.674286/full#supplementary-material

12. Kim M, Morales LD, Jang IS, Cho YY, Kim DJ. Protein Tyrosine Phosphatases as Potential Regulators of STAT3 Signaling. Int J Mol Sci (2018) 19(9):2708. doi: 10.3390/ijms19092708
13. Sun X, Wang J, Huang M, Chen T, Chen J, Zhang F, et al. STAT3 Promotes Tumour Progression in Glioma by Inducing FOXP1 Transcription. J Cell Mol Med (2022) 22(11):5629–38. doi: 10.1111/jcmm.13837
14. Tan MSY, Sandanaraj E, Chong YK, Lim SW, Koh LWH, Ng WH, et al. A STAT3-Based Gene Signature Stratifies Glioma Patients for Targeted Therapy. Nat Commun (2019) 10(1):3601. doi: 10.1038/s41467-019-11164-x
15. Ganapathy-Kanniappan S, Geschwind JF. Tumor Glycolysis as a Target for Cancer Therapy: Progress and Prospects. Mol Cancer (2013) 12:152. doi: 10.1186/1476-4598-12-152
16. Li H, Liang Q, Wang L. Icaritin Inhibits Glioblastoma Cell Viability and Glycolysis by Blocking the IL-6/Stat3 Pathway. J Cell Biochem (2018) 120 (5):7257–64. doi: 10.1002/jcb.28000
17. Yoon S, Kim S-Y, Nam D. Improving Gene-Set Enrichment Analysis of RNA-Seq Data With Small Replicates. PLoS One (2016) 11(11):e0165919. doi: 10.1371/journal.pone.0165919
18. Love MI, Huber W, Anders S. Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With DESeq2. Genome Biol (2014) 15(12):1–21. doi: 10.1186/s13059-014-0550-8
19. Xu C-F, Liu Y, Shen S, Zhu Y-H, Wang J. Targeting Glucose Uptake With siRNA-Based Nanomedicine for Cancer Therapy. Biomaterials (2015) 51:1–11. doi: 10.1016/j.biomaterials.2015.01.068
20. Hosseini SM, Okoye I, Chaleshtari MG, Hazhirkarzar B, Mohamadnejad J, Azizi G, et al. E2 Ubiquitin-Conjugating Enzymes in Cancer: Implications for Immunotherapeutic Interventions. Clin Chim Acta (2019) 498:126–34. doi: 10.1016/j.cca.2019.08.020
21. Cai P, Guo W, Yuan H, Li Q, Wang W, Sun Y, et al. Expression and Clinical Significance of Tyrosine Phosphatase SHP-2 in Colon Cancer. BioMed Pharmacother (2014) 68(3):285–90. doi: 10.1016/j.biopha.2013.10.012
22. Chong PSY, Zhou J, Lim JSL, Hee YT, Chooi JY, Chung TH, et al. IL6 Promotes a STAT3-PRL3 Feedforward Loop Via SHP2 Repression in Multiple Myeloma. Cancer Res (2019) 79(18):4679–88. doi: 10.1158/0008-5472.CAN-19-0343
23. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, Princen F, et al. Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis. Cancer Cell (2011) 19(5):629–39. doi: 10.1016/j.ccr.2011.03.023
24. Han W, Shi J, Cao J, Dong B, Guan W. Emerging Roles and Therapeutic Interventions of Aerobic Glycolysis in Glioma. Onco Targets Ther (2020) 13:6937. doi: 10.2147/OTT.S260376
25. Li M, Jin R, Wang W, Zhang T, Sang J, Li N, et al. STAT3 Regulates Glycolysis Via Targeting Hexokinase 2 in Hepatocellular Carcinoma Cells. Oncotarget (2017) 8(15):24777–84. doi: 10.18632/oncotarget.15801
26. Zhang XY, Li M, Sun K, Chen XJ, Meng J, Wu L, et al. Decreased Expression of GRIM-19 by DNA Hypermethylation Promotes Aerobic Glycolysis and Cell Proliferation in Head and Neck Squamous Cell Carcinoma. Oncotarget (2015) 6(1):101–15. doi: 10.18632/oncotarget.2684
27. Shi Y, Guryanova OA, Zhou W, Liu C, Huang Z, Fang X, et al. Ibrutinib Inactivates BMX-STAT3 in Glioma Stem Cells to Impair Malignant Growth and Radioresistance. Sci Transl Med (2018) 10(443):eaah6816. doi: 10.1126/scitranslmed.aah6816
28. Ou B, Sun H, Zhao J, Xu Z, Liu Y, Feng H, et al. Polo-Like Kinase 3 Inhibits Glucose Metabolism in Colorectal Cancer by Targeting HSP90/STAT3/HK2 Signaling. J Exp Clin Cancer Res (2019) 38(1):1–12. doi: 10.1186/s13046-019-1418-2
29. Li P, Lv H, Xu M, Zang B, Ma Y. ARHGAP6 Promotes Apoptosis and Inhibits Glycolysis in Lung Adenocarcinoma Through STAT3 Signaling Pathway. Cancer Manage Res (2020) 12:9665. doi: 10.2147/CMAR.S257759

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Pan, Bao, Zhang and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.